CureVac (NASDAQ:CVAC) Stock Price Down 3.7% – What’s Next?

CureVac (NASDAQ:CVAC) fell 3.7% during mid-day trading on Wednesday . The stock traded as low as $4.00 and last traded at $3.99. 98,708 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,485,596 shares. The stock had previously closed at $4.14.

CureVac Stock Down 3.8 %

The firm has a market cap of $891.71 million, a price-to-earnings ratio of 7.23 and a beta of 2.50. The stock has a 50-day moving average of $3.26 and a 200-day moving average of $3.18. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05.

Institutional Trading of CureVac

Hedge funds have recently bought and sold shares of the company. Barclays PLC acquired a new position in CureVac during the 3rd quarter worth $67,000. Public Employees Retirement System of Ohio acquired a new stake in CureVac in the third quarter worth about $91,000. Jane Street Group LLC grew its position in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after buying an additional 55,867 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in CureVac during the 3rd quarter valued at about $35,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock worth $127,000 after buying an additional 16,792 shares in the last quarter. 17.26% of the stock is currently owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.